News | November 01, 2010

Boston Scientific to Sell Neurovascular Business

November 2, 2010 – Boston Scientific will sell its neurovascular business to Stryker for $1.5 billion in cash. Of that purchase price, $1.4 billion will be paid at closing, and the remaining $100 million will be paid upon commercialization of the Target Detachable Coils. Several manufacturing facilities will also be transferred to Stryker.

Boston Scientific’s neurovascular business develops less-invasive medical technologies used to treat brain aneurysms and other types pf cerebrovascular disease.

“We deeply appreciate the contributions of our neurovascular employees and wish them continued success going forward in this new venture,” said Ray Elliott, president and CEO of Boston Scientific. “We believe this transaction will prove to be a win-win for all parties.”

For more information: www.bostonscientific.com, www.stryker.com

Related Content

Majority of High-Risk Stroke Patients Not Being Screened for Common Risk Factors
News | Stroke| September 28, 2017
September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwid
SanBio Receives $20 Million Grant for Stroke Clinical Trial
News | Stroke| July 12, 2017
July 12, 2017 — SanBio Inc.
German Workshop Highlights Possibilities of Perfusion MRI
News | Stroke| July 03, 2017
When diagnosing strokes and heart diseases or looking at tumors, perfusion magnetic resonance imaging (MRI) offers a...
Stroke History Higher in Asymptomatic Versus Symptomatic Atrial Fibrillation Patients
News | Stroke| June 28, 2017
Newly diagnosed asymptomatic atrial fibrillation patients have a higher rate of previous stroke than those with...
Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial
News | Stroke| May 12, 2017
More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial...
hyperbaric oxygen treatment, HBOT, stroke, David Steenblock D.O.

Image courtesy of David Steenblock, D.O.

News | Stroke| April 06, 2017
David Steenblock, D.O., an osteopathic physician based in San Clemente, Calif., recently discussed his use of...
marijuana use, increased risk, stroke, heart failure, ACC 2017 study
News | Stroke| March 15, 2017
Using marijuana raises the risk of stroke and heart failure even after accounting for demographic factors, other health...
DEFUSE-2 study, MRI, brain bleeding risk, post-stroke treatment, NIH

This image combines pre- and post-treatment scans from the same patient. Analysis of the two scans revealed that the area and size of post-treatment bleeding corresponded to blood-brain barrier disruption (shown in green, yellow and red) prior to therapy. Image courtesy of Richard Leigh, NINDS.

News | Stroke| June 29, 2016
In a study of stroke patients, investigators confirmed through magnetic resonance imaging (MRI) brain scans an...
hemmorhagic stroke, blood pressure management, ATACH II trial, NINDS

Brain scan showing damage caused by bleeding during a hemorrhagic stroke. Image courtesy of Adnan I Qureshi, M.D., University of Minnesota.

News | Stroke| June 09, 2016
June 9, 2016 — An international stroke study
Overlay Init